Pathios Therapeutics Limited announced that it will receive series B round of funding on April 18, 2024.

On same date, the company has received $25 million in funding in its first tranche. The transaction included participation from new investor Bristol-Myers Squibb Company, existing investors Canaan Management, Inc., and Brandon Capital Partners.